Key result
Myofibroblasts from diverse progenitors drive pathological matrix remodeling in atherosclerosis and aortic valve sclerosis.
Why the study?
Diverse mechanisms drive fibrosis in cardiovascular pathologies, making it crucial to understand their impact and contribution to control fibrosis before severe pathological consequences develop.
Understanding the diverse mechanisms driving fibrosis in cardiovascular pathologies is crucial for developing strategies to control fibrosis before severe pathological consequences occur.
Answers are grounded in this paper and cite their sources.
May inform antifibrotic strategies in atherosclerosis and aortic valve sclerosis; leaves open clinical translation pending prospective validation.
Cardiovascular diseases, such as atherosclerosis and aortic valve sclerosis (AVS) are driven by inflammation induced by a variety of stimuli, including low-density lipoproteins (LDL), reactive oxygen species (ROS), infections, mechanical stress, and chemical insults. Fibrosis is the process of compensating for tissue injury caused by chronic inflammation. Fibrosis is initially beneficial and maintains extracellular homeostasis. However, in the case of AVS and atherosclerosis, persistently active resident fibroblasts, myofibroblasts, and smooth muscle cells (SMCs) perpetually remodel the extracellular matrix under the control of autocrine and paracrine signaling from the immune cells. Myofibroblasts also produce pro-fibrotic factors, such as transforming growth factor-β1 (TGF-β1), angiotensin II (Ang II), and interleukin-1 (IL-1), which allow them to assist in the activation and migration of resident immune cells. Post wound repair, these cells undergo apoptosis or become senescent; however, in the presence of unresolved inflammation and persistence signaling for myofibroblast activation, the tissue homeostasis is disturbed, leading to excessive extracellular matrix (ECM) secretion, disorganized ECM, and thickening of the affected tissue. Accumulating evidence suggests that diverse mechanisms drive fibrosis in cardiovascular pathologies, and it is crucial to understand the impact and contribution of the various mechanisms for the control of fibrosis before the onset of a severe pathological consequence.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2019) conducted a review in Atherosclerosis and Aortic Valve Sclerosis (AVS). Myofibroblasts originating from diverse progenitor cells drive pathological extracellular matrix remodeling in atherosclerosis and aortic valve sclerosis via TGF-β1, IL-1β, and Angiotensin II signaling.
Synapse has enriched 10 related papers. Consider them for comparative context: